250 related articles for article (PubMed ID: 2829381)
1. Potentiation by heparin fragments of thrombolysis induced with human tissue-type plasminogen activator or human single-chain urokinase-type plasminogen activator.
Stassen JM; Juhan-Vague I; Alessi MC; De Cock F; Collen D
Thromb Haemost; 1987 Oct; 58(3):947-50. PubMed ID: 2829381
[TBL] [Abstract][Full Text] [Related]
2. Synergistic effect on thrombolysis of sequential infusion of tissue-type plasminogen activator (t-PA) single-chain urokinase-type plasminogen activator (scu-PA) and urokinase in the rabbit jugular vein thrombosis model.
Collen D; Stassen JM; De Cock F
Thromb Haemost; 1987 Oct; 58(3):943-6. PubMed ID: 3124288
[TBL] [Abstract][Full Text] [Related]
3. [Low molecular weight heparin CY 222 (Choay) potentiates the thrombolytic effect of 1-PA in rabbits with experimental thrombosis of the jugular vein].
Juhan-Vague I; Stassen JM; Alessi MC; de Cock F; Serradimigni A; Collen D
J Mal Vasc; 1987; 12 Suppl B():64-5. PubMed ID: 2834493
[TBL] [Abstract][Full Text] [Related]
4. Potentiation by heparin fragment CY 222 (Choay) of thrombolysis induced by human tissue-type plasminogen activator.
Juhan-Vague I; Stassen JM; Alessi MC; Elias A; Aillaud MF; Serradimigni A; Collen D
Semin Thromb Hemost; 1989 Oct; 15(4):390-4. PubMed ID: 2554499
[No Abstract] [Full Text] [Related]
5. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
Collen D; De Cock F; Demarsin E; Lijnen HR; Stump DC
Thromb Haemost; 1986 Aug; 56(1):35-9. PubMed ID: 3095946
[TBL] [Abstract][Full Text] [Related]
6. Potentiation by Lys-plasminogen of clot lysis by single or two chain urokinase-type plasminogen activator or tissue-type plasminogen activator.
Watahiki Y; Scully MF; Ellis V; Kakkar VV
Thromb Haemost; 1989 Jun; 61(3):502-6. PubMed ID: 2508259
[TBL] [Abstract][Full Text] [Related]
7. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J
Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138
[TBL] [Abstract][Full Text] [Related]
8. Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinase.
Dewerchin M; Vandamme AM; Holvoet P; De Cock F; Lemmens G; Lijnen HR; Stassen JM; Collen D
Thromb Haemost; 1992 Aug; 68(2):170-9. PubMed ID: 1412163
[TBL] [Abstract][Full Text] [Related]
9. The nature of synergy between tissue-type and single chain urokinase-type plasminogen activators.
Fry ET; Mack DL; Sobel BE
Thromb Haemost; 1989 Nov; 62(3):909-16. PubMed ID: 2512679
[TBL] [Abstract][Full Text] [Related]
10. Effect of standard heparin and a low molecular weight heparin on thrombolytic and fibrinolytic activity of single-chain urokinase plasminogen activator in vitro.
Lourenço DM; Dosne AM; Kher A; Samama M
Thromb Haemost; 1989 Nov; 62(3):923-6. PubMed ID: 2556812
[TBL] [Abstract][Full Text] [Related]
11. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site.
Colucci M; Cavallo LG; Agnelli G; Mele A; Bürgi R; Heim J; Semeraro N
Thromb Haemost; 1993 May; 69(5):466-72. PubMed ID: 8391727
[TBL] [Abstract][Full Text] [Related]
12. [New thrombolytic agents in myocardial infarction].
Charbonnier B; Lang M; Brochier M
Arch Mal Coeur Vaiss; 1987 Nov; 80(12):1785-91. PubMed ID: 3128222
[TBL] [Abstract][Full Text] [Related]
13. Tissue-type plasminogen activator (t-PA) and single chain urokinase-type plasminogen activator (scu-PA): potential for fibrin-specific thrombolytic therapy.
Collen D
Prog Hemost Thromb; 1986; 8():1-18. PubMed ID: 3104986
[No Abstract] [Full Text] [Related]
14. Synergism of tissue-type plasminogen activator (t-PA) and single-chain urokinase-type plasminogen activator (scu-PA) on clot lysis in vitro and a mechanism for this effect.
Gurewich V; Pannell R
Thromb Haemost; 1987 Jun; 57(3):372-3. PubMed ID: 3116707
[No Abstract] [Full Text] [Related]
15. Coronary thrombolysis in man with pro-urokinase: improved efficacy with low dose urokinase.
Kasper W; Meinertz T; Hohnloser S; Engler H; Hasler C; Rössler W; Wolf H; Welzel D; Just H; Gurewich V
Klin Wochenschr; 1988; 66 Suppl 12():109-14. PubMed ID: 3126340
[TBL] [Abstract][Full Text] [Related]
16. Thrombolytic activity of two chimeric recombinant plasminogen activators (FK2tu-PA and K2tu-PA) in rabbits.
Agnelli G; Pascucci C; Colucci M; Nenci GG; Mele A; Bürgi R; Heim J
Thromb Haemost; 1992 Sep; 68(3):331-5. PubMed ID: 1440500
[TBL] [Abstract][Full Text] [Related]
17. Bolus dose response characteristics of single chain urokinase plasminogen activator and tissue plasminogen activator in a dog model of arterial thrombosis.
Badylak SF; Voytik S; Klabunde RE; Henkin J; Leski M
Thromb Res; 1988 Nov; 52(4):295-312. PubMed ID: 3144052
[TBL] [Abstract][Full Text] [Related]
18. Inhibition in purified systems and in human plasma of chimaeric plasminogen activators consisting of the NH2-terminal region of tissue-type plasminogen activator and the COOH-terminal region of urokinase-type plasminogen activator.
Lijnen HR; Nelles L; Van Hoef B; De Cock F; Collen D
Thromb Haemost; 1988 Oct; 60(2):247-50. PubMed ID: 3146141
[TBL] [Abstract][Full Text] [Related]
19. Comparative effects of staphylokinase and alteplase in rabbit bleeding time models.
Vanderschueren S; Collen D
Thromb Haemost; 1996 May; 75(5):816-9. PubMed ID: 8725729
[TBL] [Abstract][Full Text] [Related]
20. [Experimental study on liquefaction of intracranial hematoma: usefulness of tissue-plasminogen activator (t-PA), a hematolytic agent, and its combination].
Ebina K; Okabe S; Manabe H; Iwabuchi T
No Shinkei Geka; 1990 Oct; 18(10):927-34. PubMed ID: 2122269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]